| Bronvermelding: | -Patsalos P N , Berry D J , Bourgeois B F et al. Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies . Epilepsia 2008 ; 49 : 1239 – 1276
-Hiemke et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. :harmacospychiatry 44:195-235
-Lindberger M , Luhr O , Johannessen S I et al. Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study . Ther Drug Monit 2003 ; 25 : 457 – 462
-Johannessen S I , Tomson T . Pharmacokinetic variability of newer
-antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006 ; 45 : 1061 – 1075
-Bockbrader H N , Wesche D , Miller R et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.Clin Pharmacokinet 2010 ; 49 : 661 – 669
-Bockbrader H N , Burger P , Knapp L et al. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures . Epilepsia 2011 ; 52 : 248 – 257
-Bockbrader H N . Clinical pharmacokinetics of gabapentin . Drugs Today 1995 ; 31 : 613 – 619
- TDM monografie Gabapentine NVZA
|
